Organoid Sciences specializes in organoid-based drug discovery and regenerative medicine, utilizing 3D cultured stem cells to create miniaturized organs that closely mimic human tissue. The company addresses the challenge of organ shortages and the need for personalized treatment options for incurable diseases through its advanced drug screening and regenerative therapeutic platforms.
Funding
$41.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The development of new drugs and regenerative therapies is hindered by the limitations of traditional 2D cell cultures and animal models, which often fail to accurately replicate human organ complexity and patient-specific responses. This leads to high failure rates in clinical trials and difficulties in developing personalized treatments for diseases with limited therapeutic options. Furthermore, organ shortages limit the availability of regenerative therapies.
Solution
Organoid Sciences addresses these challenges by utilizing 3D cultured stem cells to create organoids, miniaturized organs that closely mimic human tissues. Their organoid-based platforms, ADIO and ATORM, facilitate drug discovery and regenerative medicine. ADIO serves as a drug development platform for Phase 0 drug evaluation, reflecting patient specificity, utilizing immune cells, and simulating the tumor microenvironment. ATORM is a regenerative therapeutic platform that offers increased effect with high reproducibility, safety due to low carcinogenicity, and high scalability for various indications, aiming to solve the problem of organ shortages.
Target Audience
The primary target audience includes pharmaceutical companies, research institutions, and clinicians involved in drug discovery, personalized medicine, and regenerative therapies.
Features
- 3D culture of stem cells to create organoids that mimic human organs.
- ADIO platform for Phase 0 drug evaluation, incorporating patient-specific responses and immune cell interactions.
- ATORM platform for regenerative therapy with high reproducibility and low carcinogenicity.
- Organoids composed of organ-specific adult stem cells for transplantation into damaged tissue.
- Capability to reproduce the cellular composition, structure, and functional specificity of organs in vitro.
- Intestinal organoids consisting of intestinal stem cells, enterocytes, Paneth cells, goblet cells, and enteroendocrine cells, with crypt and villus structures.